Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Maze Therapeutics, Inc.NASDAQ: MAZE
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $444K fell 35.1% year over year, behind the -28.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.0% from the prior quarter. Over 3 fiscal years it compounded at -14.3% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -35.1% toward the trailing-twelve-month pace of -28.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.4M USD
- Year-over-year change
- -27.1%
- 3-year CAGR
- -14.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.4M | -27.1% |
| FY2024 | 2024-12-31 | 3.3M | -19.4% |
| FY2023 | 2023-12-31 | 4.09M | +7.0% |
| FY2022 | 2022-12-31 | 3.82M | — |
Depreciation & Amortization vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.6% is the 7th highest of 8, against a peer median of +23.8%.
- Depreciation & amortization amounts to 10.8% of revenue for MAZE, versus a peer median of 3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.3M USD | +97.1% | -33.0% | 5.5% | |
| LTM Sep 2026 | $52.78M USD | -3.5% | +43.1% | 8.1% | |
| LTM Mar 2026 | $3.37M USD | +51.2% | +38.8% | 0.8% | |
| FY2025 | €3.22M EUR | -38.0% | +23.8% | 71.9% | |
| LTM Mar 2026 | $2.16M USD | -28.6% | -14.3% | 10.8% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.64M USD | +3.3% | +40.6% | 1.7% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K USD | +39.8% | +18.2% | 2.3% |
| LTM Mar 2026 | $52K USD | +23.8% | — | — | |
| Peer median (excluding MAZE) | — | +23.8% | +31.3% | 3.9% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.